Clinical trials: Spondyloarthropathies
Psoriatic Arthritis, Flare Up, Symptom
PsA Digital Phenotyping and Inflammation Drivers Study
The goal of this observational study is to develop and internally validate a machine learning model for detecting flare using a digital biomarker and a machine learning model for predicting flare, in patients with psoriatic…
- Conditions
- Psoriatic Arthritis, Flare Up, Symptom, Psoriatic Arthritis Aggravated
- Trial name
- PDPID (NCT06347237)
- Volunteers
- 600 people
- Sponsor
- Jolanda Luime
Arthritis, Psoriatic
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
The purpose of this study is to evaluate the efficacy of icotrokinra (JNJ-77242113) compared to placebo in biologic-experienced and biologic-naive participants with active psoriatic arthritis (PsA) by assessing the reduction in…
- Trial name
- ICONIC-PsA 2 (NCT06807424)
- Testing
- Icotrokinra
- Where
- 236 sites in United States, Argentina and 22 more
- Volunteers
- 750 people
- Sponsor
- Janssen Research & Development, LLC
Arthritis, Psoriatic
A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis
The purpose of this study is to evaluate the safety and efficacy (improvement of signs and symptoms) of subcutaneous (under the skin) injections of golimumab for the treatment of active psoriatic arthritis (PsA).
- Trial name
- GO-REVEAL (NCT00265096)
- Testing
- golimumab
- Where
- 51 sites in United States, Belgium and 4 more
- Volunteers
- 407 people
- Sponsor
- Centocor, Inc.
Ankylosing Spondylitis
Double Blind, Placebo Controlled Study to Assess Efficacy of AIN457 in Moderate to Severe Ankylosing Spondylitis
Evaluate the safety, tolerability and pharmacokinetics of AIN457 when administered as treatment of moderate to severe ankylosing spondylitis (AS).
- Trial name
- NCT00809159
- Testing
- AIN457
- Where
- 20 sites in United States, Germany and 2 more
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis Vulgaris, Psoriasis Arthropathica
Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Psoriasis)
To collect information on the safety and effectiveness of Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" against psoriasis vulgaris, psoriasis arthropathica, pustular psoriasis, or erythrodermic psoriasis under…
- Conditions
- Psoriasis Vulgaris, Psoriasis Arthropathica, Pustular Psoriasis, Erythrodermic Psoriasis
- Trial name
- NCT03885089
- Testing
- Infliximab [infliximab biosimilar 3]
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- Pfizer
Spondyloarthritis, Crohn's Disease
Effectiveness and Safety of Spondylitis Related to Inflammatory Bowel Disease
Adalimumab is an antibody treatment that targets and neutralizes a molecule produced in the body that is associated with inflammation, tumor necrosis factor (TNF).
- Trial name
- NCT00972218
- Testing
- Adalimumab
- Where
- Canada
- Sponsor
- University of Alberta
Psoriatic Arthritis, Psoriasis
Psorcast Mobile Study
The purpose of this study is to understand variation in the symptoms of psoriasis and psoriatic arthritis using simple, scalable smartphone-based measurements.
- Conditions
- Psoriatic Arthritis, Psoriasis, Psoriatic Conditions, Dermatologic Disease
- Trial name
- NCT05621369
- Testing
- Participant self-assessment surveys, Psoriasis Draw, Psoriasis Area Photo
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Sage Bionetworks
Spondylarthropathies
Evaluation of a Protocol for Dose Reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF
The purpose of this study is to demonstrate that patients with Spondylarthropathies in remission under antiTNF therapy, can maintain the remission with a maintenance dose inferior to the currently recommended dose schedule.
- Trial name
- REDES-TNF (NCT01604629)
- Testing
- Reduced doses of anti-TNF, Stable doses of anti-TNF
- Where
- 31 sites in Spain
- Volunteers
- 120 people
- Sponsor
- Spanish Clinical Pharmacology Society
Axial Spondyloarthritis
Safety and Efficacy of Tofacitinib in the Treatment of NSAID Refractory Axial Spondyloarthritis:A Clinical Trial
Title Efficacy and Safety of Tofacitinib in the Treatment of NSAID-Refractory Axial Spondyloarthritis: A Clinical Trial Background: Axial spondyloarthritis (axSpA) is a chronic systemic inflammatory rheumatic disease affecting…
- Trial name
- NCT03738956
- Testing
- Tofacitinib
- Where
- Bangladesh
- Volunteers
- 30 people
- Sponsor
- Globe Pharmaceuticals Limited
Axial Spondyloarthritis, Ankylosing Spondylitis
French Validation of Axial Spondyloarthritis Questionnaires (Val-SpA)
The aim is to do a French linguistic validation of three questionnaires used in axial Spondyloarthritis (BASFI, BAS-G, Dougados Functional Index).
- Trial name
- Val-SpA (NCT04212806)
- Where
- 2 sites in France
- Volunteers
- 5 people
- Sponsor
- University Hospital, Grenoble
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
This is a study to compare the efficacy of bimekizumab versus placebo and an active comparator in the treatment of subjects with moderate to severe chronic plaque psoriasis (PSO).
- Conditions
- Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
- Trial name
- BE VIVID (NCT03370133)
- Testing
- Bimekizumab, Ustekinumab
- Where
- 105 sites in United States, Australia and 9 more
- Volunteers
- 567 people
- Sponsor
- UCB Biopharma SRL
Spondyloarthritis, Axial
Baricitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Comparison With Tofacitinib
Axial Spondylarthritis (ax-SpA) is an important cause of inflammatory back pain in young adults. Janus kinase inhibitors (JAKi) has been approved for treatment of ax-SpA.
- Trial name
- NCT06114407
- Testing
- Baricitinib 2mg, Tofacitinib 5 mg
- Where
- Bangladesh
- Volunteers
- 184 people
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Spondylarthropathies
Mechanism of Action of Anti-IL17 Therapy in Peripheral Spondyloarthritis
The purpose of this study is to determine the mechanism of action on target tissue level of anti Interleukine-17 (anti-IL-17) an therapy in peripheral spondyloarthritis.
- Trial name
- MoA aIL-17 (NCT03358134)
- Testing
- Secukinumab
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Covid-19 Infection, Rheumatoid Arthritis
IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT
This study aims to evaluate the experience of Alberta patients with inflammatory arthritis who participate in the the RAPPORT-ONTRAAC registry during the COVID-19 pandemic, specifically comparing the experience of those taking…
- Conditions
- Covid-19 Infection, Rheumatoid Arthritis, Psoriatic Arthritis, Hydroxychloroquine
- Trial name
- IMPACT (NCT04347798)
- Testing
- Hydroxychloroquine/Chloroquine
- Where
- Canada
- Volunteers
- 773 people
- Sponsor
- University of Alberta
Axial Spondyloarthritis, Ankylosing Spondylitis
A Study to Assess the Safety of Subcutaneous Secukinumab for Treatment in Adult Indian Participants With Axial Spondyloarthritis (axSpA), Ankylosing Spondylitis (AS), and Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
The aim of this study is to assess the safety of secukinumab in Indian adult participants with axSpA, AS, and nr-axSpA over a 16-week treatment period.
- Conditions
- Axial Spondyloarthritis, Ankylosing Spondylitis, Non-Radiographic Axial Spondyloarthritis
- Trial name
- NCT07737730
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Axial Spondyloarthritis
Add-on Therapy for Axial Spondyloarthritis
Rationale: Recent investigations suggest that, through certain concentration/meditation techniques, it is possible to modulate autonomic activity.
- Trial name
- NCT02744014
- Testing
- Add-on Therapy for Axial Spondyloarthritis
- Where
- 2 sites in Netherlands
- Volunteers
- 24 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Axial Spondyloarthritis, Crohn Disease
MRE as a Screening Tool for axSpA in IBD
This study aims to assess the effectiveness (specificity and sensitivity) of using magnetic resonance enterography (MRE) as a screening tool for axial spondyloarthritis (axSpA) in patients with Crohns disease.
- Trial name
- ProSpA-CD (NCT03817983)
- Testing
- MRE review for evidence of axSpA in SIJs, Clinical assessment and dedicated MRI of the spine and pelvis
- Where
- United Kingdom
- Volunteers
- 259 people, healthy volunteers welcome
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Axial Spondyloarthritis and Ankylosing Spondylitis
The Effect of Aerobic Exercises and Yoga Exercises in Axial Spondyloarthritis
Axial Spondyloarthritis (AxSpA), mainly affecting the axial skeleton and sacroiliac joints, is a chronic, systemic, inflammatory disease that causes structural and functional disorders.
- Trial name
- NCT06138717
- Testing
- yoga based exercises
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Ankara City Hospital Bilkent
Ankylosing Spondylitis
An Observational Study to Evaluate Safety and Efficacy of Remsima™ in Patients With Ankylosing Spondylitis
An Observational, Prospective Cohort Study to Evaluate Safety and Efficacy of RemsimaTM in Patients with Ankylosing Spondylitis
- Trial name
- NCT02557308
- Volunteers
- 329 people
- Sponsor
- Celltrion
Axial Spondyloarthritis, Arthritis, Rheumatoid
The Role of Microbiome on Biological Therapy Efficacy in axSpA and RA
Spondyloarthritis (SpA) and Rheumatoid arthritis (RA) are among the most common chronic inflammatory rheumatic diseases. Introduction of Tumor Necrosis Factor alpha inhibitors (TNFi) to the therapeutic strategy improved acute…
- Trial name
- MicroSpA & RA (NCT04973787)
- Testing
- biological disease-modifying antirheumatic drugs (bDMARDs)
- Where
- 10 sites in Portugal
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Universidade Nova de Lisboa